Finance

Lists
4AJ0:FRA
ALK-Abello A/S
€28.00
-0.07%
(-0.020) 1D
Sep 4, 4:55:44 PM GMT+2  ·   EUR
All symbols
SymbolPriceChange% Change
Generating top insights for 4AJ0...
Open
€27.94
High
€28.18
Low
€27.94
Mkt. cap
42.54B
Avg. vol.
15.00
Volume
8.00
52-wk high
€36.28
52-wk low
€26.22
No. of employees
3K
Open
€27.94
High
€28.18
Low
€27.94
Mkt. cap
42.54B
Avg. vol.
15.00
Volume
8.00
52-wk high
€36.28
52-wk low
€26.22
No. of employees
3K
Profile
ALK-Abelló A/S, also commonly known as ALK, is a Denmark-based pharmaceutical company which specializes in the development and manufacturing of allergy immunotherapy products for the prevention and treatment of allergy. It is one of the world's largest makers of allergy immunotherapy products with 67% of its revenue coming from sales in Europe. Wikipedia
About ALK-Abello A/S
CEOPeter Halling
Employees2.77K
Founded1923
Headquarters-
SectorPharmaceutical industry
Websitealk.net
Previous reportsAll values in DKK
Loading Previous Earnings...
Income statement
Revenue
Net income
All values in DKK
Sep 2025
Dec 2025
Mar 2026
Jun 2026
Revenue
1.53B
1.73B
1.77B
1.80B
Cost of goods sold
487.00M
543.00M
543.00M
600.00M
Cost of revenue
487.00M
543.00M
543.00M
600.00M
Research and development expenses
145.00M
189.00M
151.00M
168.00M
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
475.00M
605.00M
507.00M
582.00M
Operating expense
620.00M
793.00M
658.00M
750.00M
Total operating expenses
1.11B
1.34B
1.20B
1.35B
Operating income
423.00M
397.00M
570.00M
445.00M
Other non operating income
-
-
-
-
EBT including unusual items
419.00M
393.00M
583.00M
452.00M
EBT excluding unusual items
419.00M
403.00M
583.00M
452.00M
Income tax expense
105.00M
127.00M
146.00M
113.00M
Effective tax rate
25.06%
32.32%
25.04%
25.00%
Other operating expenses
-
-1.00M
-
-
Net income
314.00M
266.00M
437.00M
339.00M
Net profit margin
20.52%
15.35%
24.68%
18.89%
Earnings per share
1.40
1.20
2.00
1.50
Interest and investment income
-
28.00M
13.00M
7.00M
Interest expense
-4.00M
-6.00M
-
-
Net interest expenses
-4.00M
22.00M
13.00M
7.00M
Depreciation and amortization charges
-
-
-
-
EBITDA
510.00M
400.00M
654.00M
531.00M
Gain or loss from assets sale
-
-
-
-
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer
Google apps